SKIN The Journal of Cutaneous Medicine

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

MG Lebwohl, J Sugarman, DM Pariser, J Bagel, T Lin, R Israel

Page S12

Poster PDF

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

Mark G Lebwohl, Jeffrey Sugarman, David M Pariser, Jerry Bagel, Cynthia Trickett, Abby Jacobson, Robert Israel

Page s38

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%

Linda Stein Gold, Jonathan S Weiss, Lawrence Green, Leon Kircik, Lauren Miller, Abby Jacobson, Susan Harris

Page s37

Poster PDF

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Andrew F Alexis, Paul S Yamauchi, Tina Lin, Gina Martin

Page S28

Poster PDF

Efficacy and Safety of Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Moderate to Severe Plaque Psoriasis of the Lower Extremities

SK Tyring, LH Kircik, PS Yamauchi, N Anbalagan, T Lin

Page S10

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion

Lina Stein Gold, Mark G Lebwohl, Neal Bhatia, Tina Lin, Radhakrishnan Pillai

Page S31

Poster PDF

Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis

L Stein-Gold, B Elewski, Z Draelos, T Lin

Page S9

Poster PDF

Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)

Brad Glick, Edward Lain, Tina Lin, Robert Israel

Page S30

Poster PDF

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Mark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, Tina Lin, Gina Martin

Page S29

Poster PDF

Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology

Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Stefan Weiss, Tina Lin, Arturo Angel, Radhakrishnan Pillai

Page S27

Poster PDF

Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis

Andrew Alexis, James Del Rosso, Tina Bhutani, Kim Papp, Abby Jacobson

Page s48

Poster PDF

Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Plaque Psoriasis in Patients with Mild Scaling and Mild Plaque Elevation

Linda Stein Gold, Emil Tanghetti, Craig Leonardi, Shawn Kwatra, Abby Jacobson

Page s22

Poster PDF

Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action

Leon Kircik, Zoe Draelos, Linda Stein Gold, Abby Jacobson

Page s131

Poster PDF

Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis

Leon Kircik, Lawrence Green, Joshua Zeichner, Javier Alonso-Llamazares, Abby Jacobson

Page s49

Poster PDF

Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area

Craig Leonardi, Linda Stein Gold, Edward Lain, Andrea Neimann, Abby Jacobson

Page s78

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion

Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai

Page s79

Poster PDF

Search

Search Results